Ofev (nintedanib) doesn’t produce a moment where you suddenly feel better. It works by slowing the rate of lung scarring, and the clinical trials that proved its effectiveness measured outcomes over 52 weeks. Most patients won’t notice a dramatic change in how they feel, because the drug’s primary job is to protect the lung function you still have rather than restore what’s already been lost. Understanding what “working” actually means with this medication is essential to staying on it long enough to benefit.
What “Working” Means With Ofev
Ofev blocks specific growth signals that drive scar tissue formation in the lungs. It interferes with fibroblast activity, the cells responsible for producing the excess collagen that stiffens lung tissue. It also slows the transformation of normal lung cells into the more aggressive scar-producing cells that accelerate fibrosis. At the cellular level, these effects begin shortly after you start taking the medication.
But the way doctors measure whether Ofev is working is by tracking your forced vital capacity (FVC), a breathing test that measures how much air you can push out of your lungs. In the landmark INPULSIS trials, patients on Ofev lost lung function about 51% more slowly than patients on placebo over 52 weeks. In concrete terms, that translated to roughly 94 to 125 fewer milliliters of lung capacity lost per year compared to placebo. This isn’t something you can feel day to day. It shows up over months of repeated lung function testing.
You Likely Won’t Feel Better, but You May Worsen More Slowly
One of the hardest parts of taking Ofev is that success looks like stability, not improvement. If your breathing stays roughly the same over six to twelve months, the drug is likely doing its job. That can feel underwhelming when you’re dealing with daily symptoms and hoping for relief.
That said, there is some evidence that Ofev does more than just protect lung function numbers. In a study of patients with progressive pulmonary fibrosis, those on Ofev experienced significantly less worsening of shortness of breath, fatigue, and the overall impact of their disease on daily life compared to placebo over 52 weeks. Cough scores actually improved slightly in the Ofev group while worsening in the placebo group. These aren’t dramatic symptom reversals, but they suggest the drug helps hold the line on quality of life in ways that go beyond what a breathing test captures.
The First Few Months: What to Expect
The first one to two months on Ofev are often the most challenging, not because the drug isn’t working yet, but because side effects tend to appear during this window. The median time for adverse effects to show up with nintedanib is about 45 days. Gastrointestinal side effects, particularly diarrhea, typically emerge within the first one to two months. Diarrhea is the most common reason people consider stopping the medication.
Your doctor will also monitor your liver function with blood tests during the first three months and periodically after that. Liver enzyme elevations can occur but are generally reversible if caught early through dose adjustment or temporary interruption of treatment.
The standard dose is 150 mg taken twice daily. If side effects become difficult to manage, your doctor may reduce the dose to 100 mg twice daily or pause treatment temporarily. The goal is to keep you on the medication consistently, since its benefit depends on sustained use over time.
When You’ll See Measurable Results
Realistically, it takes at least six to twelve months of regular lung function testing to see whether Ofev is slowing your decline. A single breathing test won’t tell the story. Your doctor needs to compare multiple measurements over time, looking for a trend line that’s flatter than what would be expected without treatment. Some patients see stable FVC values for a year or more, while others still decline but at a slower pace than they otherwise would.
There is no blood test or scan that shows Ofev “kicking in” at a specific point. The drug reaches effective levels in your bloodstream within hours of your first dose, but the clinical benefit, preventing future scarring, accumulates gradually and only becomes visible through repeated measurements.
Long-Term Use and Sustained Benefit
Ofev is designed to be taken indefinitely. In the INPULSIS-ON extension study, 734 patients continued treatment for a median of nearly 45 months, with some staying on the drug for over five years. The safety profile remained consistent with what was seen in shorter trials, with no new safety concerns emerging over time.
About 5% of patients who had been on Ofev from the start of the original trial permanently stopped due to diarrhea, while 10% of those who began Ofev for the first time in the extension study discontinued for the same reason. The most common reason for permanent discontinuation overall was progression of the underlying disease itself, not the medication’s side effects. This underscores an important reality: Ofev slows fibrosis but does not stop it entirely, and some patients will still experience disease progression despite treatment.
Staying on the medication through the difficult early weeks is important. The side effects that feel most intense in months one and two often become more manageable over time, and the protective benefit of the drug builds with each month of consistent use.